Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. àíàëèç êðîâè - íèçêèé ãåìîãëîáèí
    îò Alyaska â ðàçäåëå Òåðàïåâò
    Îòâåòîâ: 7
    : 01.09.2004, 19:30
  2. íèçêèé áåëîê è àëüáóìèí êðîâè
    îò nelli â ðàçäåëå Òåðàïåâò
    Îòâåòîâ: 15
    : 01.09.2004, 19:30
  3. íèçêèé ñàõàð êðîâè
    îò ìàéêî â ðàçäåëå Òåðàïåâò
    Îòâåòîâ: 3
    : 01.09.2004, 19:30
  4. Çäðàâñòâóéòå. Àíàëèç êðîâè ïîêàçàë íèçêèé ãåìîãëîáèí: 102. Ýðèòðîöèòû ÷óòü ...
    îò Þëèÿ â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 1
    : 02.08.2004, 04:32
  5. Îòâåòîâ: 2
    : 28.07.2004, 07:00
  1. nelli
    #1
    ×èòàòåëü Íåäóã.Ðó
    çäðàâñòâóéòå, ìåíÿ ñ ïîëãîäà íàçàä ñòàëè ìó÷àòü îòåêè íîã,

    ëèöà. îáñëåäîâàíèÿ ïîêàçàëè, ÷òî â êðîâè î÷åíü íèçêèé îáùèé áåëîê - 35-37 ã/ë, è àëüáóìèí - 26 ã/ë. â ìî÷å áåëîê íå îáíàðóæèëè, è âîîáùå íèêàêèõ äðóãèõ îòêëîíåíèé íå âûÿâèëè. ïðåäâàðèòåëüíûé äèàãíîç - èììóíîäåôèöèò íåÿñíîé ýòèîëîãèè. íèêàêîãî ëå÷åíèÿ íå ïðåäëàãàþò, òîëüêî 1 ðàç â ìåñÿö ïîëó÷àþ ïîðöèþ èììóíîãëîáóëèíà è àëüáóìèíà. ìíå 32 ãîäà, íèêîãäà íè÷åì ñåðüåçíûì íå áîëåëà, çàíèìàëàñü ñïîðòîì. ó ìåíÿ ïîäîçðåíèÿ, ÷òî ÿ ìîãëà "ïîñàäèòü" ïå÷åíü, êîãäà ïðèíèìàëà ïîä ðóêîâîäñòâîì äåðìàòîëîãà ðîàêóòàí. ×òî âû ïîñîâåòóåòå â òàêîé ñèòóàöèè? çàðàíåå áëàãîäàðíà

  2. Dr. Vad
    #2
    ×èòàòåëü Íåäóã.Ðó
    Åñëè ìîæíî, ïðèâåäèòå áèîõ. àíàëèç êðîâè ïîëíîñòüþ. Åñòü ëè âîçìîæíîñòü ñäåëàòü ïðîòðîìáèí(îâûé èíäåêñ)?

  3. rodionov
    #3
    ×èòàòåëü Íåäóã.Ðó
    Êàê Âû ïèòàåòåñü? Âåãåòàðèàíñòâî /ïîñò??

  4. nelli
    #4
    ×èòàòåëü Íåäóã.Ðó
    Êàê Âû ïèòàåòåñü? Âåãåòàðèàíñòâî /ïîñò??

    Çäðàâñòâóéòå, ïèòàþñü õîðîøî. Ìÿñî, ÿéöà, ñûð ... Âñå åì, ïîñò íå ñîáëþäàþ. Ñ÷èòàþ, ÷òî ñ åäîé ïîëó÷àþ äîñòàòî÷íî áåëêà. Çà ïîñëåäíèå ãîä-äâà íè÷åãî ìåíÿëîñü â ýòîì ñìûñëå.

  5. nelli
    #5
    ×èòàòåëü Íåäóã.Ðó
    Åñëè ìîæíî, ïðèâåäèòå áèîõ. àíàëèç êðîâè ïîëíîñòüþ. Åñòü ëè âîçìîæíîñòü ñäåëàòü ïðîòðîìáèí(îâûé èíäåêñ)?

    Ïðî ýòî íå ñëûøàëà, ïîïðîáóþ ñðîñèòü ó âðà÷à.

    Ïîñëåäíèé àíàëèç êðîâè òàêîé (èçâèíèòå, åñëè ÷òî-òî íåêîððåêòíî íàïèøó): CR P 0,4 mg/l, iCA 1,16 mmol/l, Bil 11 nmol/l, Krea 59 nmol/l, ALT 24 u/l, AST 31 U/l, LDH 323 u/l îáùèé áåëîê 40 g/l, All 25g/l, Alp 70 U/l, IgA 0,91 g/l, IgG 2,5g/l, IgM 0,47 g/l.

    Åùå åñòü òàêèå öèôðû: WBC 7.07 [10^9/L], RBC 5.92 [10^12/L], HGB 174 + [g/l], HCT 52.4 +[%], MCV 88.5[fL],MCH 29.4 [pg], MCHC 332 [g/l], PLT 280 [10^9/L], RDW-SD 42.0 [fL], RDW-CV 12.9 [%], PDW 13.6[fL], MPV 11.1 [fL], P-LCR 34.0[%].

  6. Dr. Vad
    #6
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Íåëëè!



    Êðîìå áåëêà, ñíèæåí èììóíîãëîáóëèí à êàê ìèíèìóì â 2,5 ðàçà è íà íèæíèõ ãðàíèöàõ íîðì - è/ãëîáóëèíû À è Ì.  öåëîì, îñòàëüíûå ïîêàçàòåëè â ïðåäåëàõ íîðìû. Âòîðîé - ýòî îáùèé àíàëèç êðîâè, â íåì ïîâûøåíû ýðèòðîöèòû, ãåìîãëîáèí, ãåìàòîêðèò (â ñðåäíåì íà 15-20%) - ãåìîêîíöåíòðàöèÿ, ÷òî ãîâîðèò î íåäîñòàòî÷íîì êîëè÷åñòâå æèäêîé ÷àñòè êðîâè (êîòîðàÿ "óõîäèò â îòåêè" èç-çà íèçêîãî ñîäåðæàíèÿ áåëêà). Àíàëèç íà ïðîòðîìáèí åùå ìîæåò íàçûâàòüñÿ INR, ïðîòðîìáèí ïî Êâèêó - áîëåå ÷óâñòâèòåëüíûé àíàëèç (÷åì àëüáóìèí èëè îáù. áåëîê), ïîêàçûâàþùèé íàðóøåíèå ñèíòåòè÷åñêîé ôóíêöèè ïå÷åíè.

     èíñòðóêöèè ê Ðîàêêóòàíó íè÷åãî íå ñêàçàíî î íàðóøåíèè ñèíòåòè÷. ô-èè ïå÷åíè ïðè ïðèåìå ïðåïàðàòà, õîòÿ òðàíçèòîðíîå ïîâûøåíèå òðàíñàìèíàç âñòðå÷àåòñÿ ÷àñòî (1/10) èëè îïèñàíû åä. ñëó÷àè ãåïàòèòà (< 1/10000). Ìîæåò áûòü, ÷òî Âàøè èçìåíåíèÿ è íå ñâÿçàíû ñ ïðèåìîì ëåêàðñòâà, à ïðîñòî ñîâïàäåíèå.

  7. nelli
    #7
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Íåëëè!



    Êðîìå áåëêà, ñíèæåí èììóíîãëîáóëèí à êàê ìèíèìóì â 2,5 ðàçà è íà íèæíèõ ãðàíèöàõ íîðì - è/ãëîáóëèíû À è Ì.  öåëîì, îñòàëüíûå ïîêàçàòåëè â ïðåäåëàõ íîðìû. Âòîðîé - ýòî îáùèé àíàëèç êðîâè, â íåì ïîâûøåíû ýðèòðîöèòû, ãåìîãëîáèí, ãåìàòîêðèò (â ñðåäíåì íà 15-20%) - ãåìîêîíöåíòðàöèÿ, ÷òî ãîâîðèò î íåäîñòàòî÷íîì êîëè÷åñòâå æèäêîé ÷àñòè êðîâè (êîòîðàÿ "óõîäèò â îòåêè" èç-çà íèçêîãî ñîäåðæàíèÿ áåëêà). Àíàëèç íà ïðîòðîìáèí åùå ìîæåò íàçûâàòüñÿ INR, ïðîòðîìáèí ïî Êâèêó - áîëåå ÷óâñòâèòåëüíûé àíàëèç (÷åì àëüáóìèí èëè îáù. áåëîê), ïîêàçûâàþùèé íàðóøåíèå ñèíòåòè÷åñêîé ôóíêöèè ïå÷åíè.

     èíñòðóêöèè ê Ðîàêêóòàíó íè÷åãî íå ñêàçàíî î íàðóøåíèè ñèíòåòè÷. ô-èè ïå÷åíè ïðè ïðèåìå ïðåïàðàòà, õîòÿ òðàíçèòîðíîå ïîâûøåíèå òðàíñàìèíàç âñòðå÷àåòñÿ ÷àñòî (1/10) èëè îïèñàíû åä. ñëó÷àè ãåïàòèòà (< 1/10000). Ìîæåò áûòü, ÷òî Âàøè èçìåíåíèÿ è íå ñâÿçàíû ñ ïðèåìîì ëåêàðñòâà, à ïðîñòî ñîâïàäåíèå.

    Ñïàñèáî áîëüøîå çà îáúÿñíåíèÿ, çàâòðà ëîæóñü â áîëüíèöó ñíîâà. Áóäó îáñëåäîâàòüñÿ äàëüøå. Íàäåþñü, ÷òî íàéäåì ïðè÷èíó ìîåãî ñîñòîÿíèÿ. Ñïàñèáî åùå ðàç!

  8. nelli
    #8
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé Dr.Vad, ïîçâîëüòå îáðàòèòüñÿ åùå ðàç ê Âàì ñ âîïðîñîì ïî ñâîåé ïðîáëåìå.

    ß ïîâòîðíî ëåæàëà â áîëüíèöå íà îáñëåäîâàíèè. Äåëàëè âñåâîçìîæíûå îáñëåäîâàíèÿ ñåðäöà, ãàñòðîñêîïèþ (áðàëè êóñî÷êè æåëóäêà, ïèùåâîäà), áèîïñèþ ïå÷åíè, ìàãíèòî-ðåçîíàíñíóþ òîìîãðàôèþ, ðåíòãåí, êîíñóëüòèðîâàëè ãèíåêîëîã, ðåâìàòîëîã, ýíäîêðèíîëîã. Èòîãè - âñå â íîðìå, òîëüêî îáíàðóæåíû èçìåíåíèÿ â ïîçâîíî÷íèêå (íåáîëüøîå ñìåùåíèå äèñêà ó 5 ïîçâîíêà) è êèñòó ùèòîâèäíîé æåëåçû (áðàëè òîæå áèîïñèþ). Âðà÷è ïîæèìàþò ïëå÷àìè, ïîòîìó ÷òî íå ìîãóò ïîíÿòü ïðè÷èíó ìîåãî ñîñòîÿíèÿ - óñòîé÷èâóþ ïîòåðþ áåëêà - ãèïîïðîòåèíåìèÿ, ãèïîãàììàãëîáóëèíåìèÿ (äàæå ïîñëå âëèâàíèÿ àëüáóìèíà - ÷åðåç 2 äíÿ ó

    ìåíÿ àíàëèçû ñòàíîâÿòñÿ ïðåæíèìè). Ìîãó ïðèâåñòè àíàëèçû:

    B-SR 1mm/t, Leuk 5.30*10 9/l, er. 5.57*10 12/l, hgb 164 g/l, HCT 48.5% MCV 87.1 fl, MCH 29.4 pg, MCHC 338 g/l, tromb 257*10 9/l. Leuk. ôîðìóëà E 1,3%, B 0,2% M 11,1%, L 7,5%, N 79,9%.

    Áèîõèìèÿ: õîëåñò. 3,4mmol/l, Na 141 mmol/l, K 4,0 mmol/l, S-AAT 1,50 g/l, S-CRP 0,3 mg/l, S-iCA 0,96 mmol/l S-Bil 9 nmol/l, S-Crea 58 nmol/l, S-ALT 30 u/l, S-AST 31 u/l, S-LDH 435 u/kl S-prot 36g/l, S-Albb 23g/l, S-ALP 58u/l, S.IgA 0,81g/l, S-IgG 2,1 g/l, IgM 0,38 g/l P-PT 67%, INR 1,18, P-APTT 36,0 sek, P-Fibr 2,63 g/l.

    Àíàëèç ìî÷è: SG 1.020, PH 6.5, LEU 25/ul, NIT neg, PRO neg, GLU norm, KET neg, UBG norm, BIL neg, ERY neg.

    Ïðîòåèíîãðàììà: îáù. áåëîê 39,0 g/l, alb 21,0 g/l, α-1 1,5 g/l, α-2 5,5 g/l, β-1 3,2 g/l, β-2 1,6g/l, γ 6,2g/l.

    ×òî åùå ìîæíî ïðåäïðèíÿòü â ýòîé ñèòóàöèè? Êóäà îáðàòèòüñÿ, ê êàêîìó ñïåöèàëèñòó?  ïðèíöèïå, êðîìå îòåêîâ íè÷åãî íå áåñïîêîèò, òÿæåëî äâèãàòüñÿ è îáóâü òàêóþ åùå íå ïðèäóìàëè, êóäà áû ïîìåùàëèñü ìîè íîãè . Èçâèíèòå, ÷òî òàê äëèííî.

    Çàðàíåå áëàãîäàðíà,

    Íåëëè

  9. Dr. Vad
    #9
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Íåëëè!



    Íå îáñëåäîâàëè ëè Âàñ íà ïðåäìåò ïîòåðè áåëêà ÷åðåç ÆÊÒ? Ñðåäè íèõ ìîæåò áûòü ëèìôîöèòàðíàÿ ãàñòðîïàòèÿ è èíòåñòèíàëüíàÿ ëèìôàíãèýêòàçèÿ. Òê íîðìàëüíàÿ áèîïñèÿ ñëèç. æåëóäêà äîëæíà èñêëþ÷èòü ïåðâîå ïðåäïîëîæåíèå, òî äëÿ èñêëþ÷åíèÿ âòîðîãî äèàãíîçà Âàñ íå äîîáñëåäîâàëè. Òåì áîëåå ÷òî èíòåñòèíàëüíîé ëèìôàíãèýêòàçèè õàðàêòåðíû 4 ïðèçíàêà, êîòîðûå ó Âàñ (ñì. òàáë.). Ïîýòîìó, ïðåäëàãàþ Âàì ñîîáùèòü ñâîé ìåéë è íà íåãî âûøëþ îïèñàíèå ïîõîæåãî êëèí. ñëó÷àÿ, ãäå ïîäðîáíî îïèñûâàþòñÿ âñå èññëåäîâàíèÿ êîòîðûå íåáõîäèìî ñäåëàòü äëÿ ïîäòâåðæäåíèÿ äèàãíîçà, êîòîðîå Âû ìîæåòå ïîêàçàòü ñâîèì ëå÷àùèì âðà÷àì (íå íóæíî îáðàùàòü âíèìàíèå íà âîçðàñò è ïðî÷. îïèñûâàåìûå ñèìïòîìû ó ïàöèåíòêè - ãëàâíîå â ýòîé ïóáëèêàöèè îïèñàíèå äèàãí. ïîäõîäà è âûÿñíåíèå ïðè÷èíû ëèìôàíãèýêòàçèè):



    J Allergy Clin Immunol. 2004 Aug;114(2):409-14.



    A 55-year-old man with hypogammaglobulinemia, lymphopenia, and unrelenting cutaneous warts.



    Lynn J, Knight AK, Kamoun M, Levinson AI.



    Pulmonary Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.



    A 55-year-old white man with a history of hypertension, fibromyalgia, and colonic polyps presented with unrelenting plantar warts on his hands and feet for the past 4 years. He was otherwise healthy and without a history of recurrent infections. Physical examination was unremarkable except for extensive warts on his hands and feet. Pertinent laboratory findings included hypoalbuminemia, hypogammaglobulinemia, and lymphopenia most severely affecting CD4(+) T cells. Testing for HIV infection was negative. This clinical and laboratory presentation suggested a combined humoral and cellular immunodeficiency syndrome that could be best explained by loss of lymphocytes, immunoglobulins, and other serum proteins. Additional immunologic testing revealed a marked reduction in peripheral blood naive (CD4(+)CD45RA(+)) T cells. A 24-hour stool collection showed a markedly elevated alpha(1)-antitrypsin level. These findings were most consistent with the diagnosis of intestinal lymphangiectasia, a type of protein-losing enteropathy associated with hypoalbuminemia, hypogammaglobulinemia, and lymphopenia, characterized by a preferential loss of naive CD4(+) T cells into the gastrointestinal tract. This case illustrates the importance of considering intestinal loss of immunoglobulins and lymphocytes in the differential diagnosis of the adult patient who presents with laboratory evidence of a combined humoral and cellular immunodeficiency. It also underscores the diagnostic utility of the clinical immunology laboratory and how flow cytometry, in particular, can contribute to an understanding of pathogenic mechanisms.



    Table II. Clinical pearl: Suspect diagnosis of intestinal lymphangiectasia

  10. aiha
    #10
    ×èòàòåëü Íåäóã.Ðó
    nelli

     ïðèâåäåííûõ Âàìè àíàëèçàõ îòìå÷àåòñÿ ñíèæåíèå êîëè÷åñòâà ëèìôîöèòîâ, IgG, â ñâÿçè ñ ÷åì íåîáõîäèìî ïðîêîíñóëüòèðîâàòüñÿ ó èììóíîëîãà, ãåìàòîëîãà.

    Ìîæíî ñäàòü àíàëèç ìî÷è, ñäåëàòü ÓÇÈ ïî÷åê è ïðè íàëè÷èè îòêëîíåíèé ïðîêîíñóëüòèðîâàòüñÿ ó íåôðîëîãà.

  11. nelli
    #11
    ×èòàòåëü Íåäóã.Ðó
    nelli

     ïðèâåäåííûõ Âàìè àíàëèçàõ îòìå÷àåòñÿ ñíèæåíèå êîëè÷åñòâà ëèìôîöèòîâ, IgG, â ñâÿçè ñ ÷åì íåîáõîäèìî ïðîêîíñóëüòèðîâàòüñÿ ó èììóíîëîãà, ãåìàòîëîãà.

    Ìîæíî ñäàòü àíàëèç ìî÷è, ñäåëàòü ÓÇÈ ïî÷åê è ïðè íàëè÷èè îòêëîíåíèé ïðîêîíñóëüòèðîâàòüñÿ ó íåôðîëîãà.

    Çäðàâñòâóéòå aiha,

    êîíñóëüòèðîâàëàñü ó ãåìàòîëîãà. Ôàêò, ÷òî î÷åíü íèçêèé IgG, íî ïî÷åìó, íèêòî ïîêà ïîíÿòü íå ìîæåò. Ïî÷êè, ïå÷åíü, ÆÊÒ, ñåðäöå, ùèòîâèäíàÿ æåëåçà â ïîðÿäêå.

    Èìååòñÿ óñòîé÷èâàÿ ïîòåðÿ áåëêà, ïðè ïåðåëèâàíèè àëüáóìèíà èëè èììóíîãëîáóëèíà ÷åðåç ïàðó äíåé àíàëèçû ñòàíîâÿòñÿ ïðåæíèìè. Ìîé äîêòîð ïëàíèðóåò â êîíöå ìàÿ èçîòîïíîå èññëåäîâàíèå (ìîæåò íåïðàâèëüíî ïåðåâåäó- "ïîìå÷åííûì àëüáóìèíîì&quot. Ïîòîì äîëüøå áóäåì äóìàòü.

  12. Dr. Vad
    #12
    ×èòàòåëü Íåäóã.Ðó
    Îáû÷íî àëüáóìèí ïîìå÷åí òåõíåöèåì-99: åãî ââîäÿò â/â è çàòåì äåëàþò ñ îïðåä. èíòåðâàëîì ñíèìêè - íà íèõ âèçóàëèçèðóþòñÿ ëîêàëèçàöèÿ è ïðîòÿæåííîñòü ó÷àñòêà ÆÊÒ, ÷åðåç êîòîðîå òåðÿåòñÿ áåëîê.

  13. aiha
    #13
    ×èòàòåëü Íåäóã.Ðó
    Çäðàâñòâóéòå nelli

    Óñèëåííîå âûäåëåíèå áåëêà èç ïëàçìû â êèøå÷íèê è ïîòåðÿ åãî ñ êàëîì ñîïðîâîæäàåò áîëåçíè æåëóäî÷íî-êèøå÷íîãî òðàêòà, áîëåçíè êðîâè, àëëåðãèþ, áîëåçíè ïî÷åê, èììóíîäåôèöèòíûå ñîñòîÿíèÿ.

    Ò. å. âîïðîñ ðåøàåòñÿ ñîâìåñòíî ãàñòðîýíòåðîëîãîì, ãåìàòîëîãîì, àëëåðãîëîãîì, íåôðîëîãîì, èììóíîëîãîì

  14. Dr. Vad
    #14
    ×èòàòåëü Íåäóã.Ðó
    Curr Treat Options Gastroenterol. 2001 Feb;4(1):39-49.



    Protein-Losing Enteropathy and Gastropathy.



    Landzberg BR, Pochapin MB.



    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University and New York-Presbyterian Hospital, 525 East 68th Street, F-231, New York, NY 10021, USA.



    The diagnosis of protein-losing enteropathy (PLE) should be considered in all patients with hypoalbuminemia and edema without other known causes, and established by plasma alpha(1)-antitrypsin (alpha(1)-AT) clearance or nuclear studies. The therapy for PLE should focus principally on the treatment of the underlying disease after it has been identified. Therapeutic goals should include improvement of hypoalbuminemia, edema, and lymphopenia. The existing primary literature for therapy of PLE syndromes consists mainly of case reports and expert opinions, subject to substantial reporting bias and unknown rates of spontaneous remission; the rarity of and the diversity among this set of diseases make future large randomized trials unlikely. Therapeutic choices, therefore, must involve clinical acumen, empiricism, and understanding of the pathophysiology of the underlying disease process, and must be tailored to each individual patient's syndrome. Dietary interventions including hypolipidic, high-protein regimens, supplemented by medium-chain triglycerides (MCTs), are extremely useful, particularly in protein loss due to increased lymphatic pressure. Corticosteroids can be very useful in certain cases of PLE (though not without substantial long-term toxicity) when clinical serologic or histologic markers of inflammatory disease are present. Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration. Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration. Surgery finds its best role in treating gastrointestinal protein loss from neoplasia, inflammatory bowel disease, and hypertrophic gastritis. Most other PLEs are distributed too widely for surgical intervention. Protein-losing gastropathy (PLG) behaves somewhat differently from the general group of PLE, marked by excellent responses to elimination of Helicobacter pylori, antisecretory therapy, and surgical resection. Protein-losing enteropathy stemming from cardiovascular disease is best treated by medical or surgical cardiovascular interventions; however, some patients may respond to mucosa-directed therapy.

  15. Gilarov
    #15
    ×èòàòåëü Íåäóã.Ðó
    Äà óæ, êîëîíîñêîïèþ ñòîèò ñäåëàòü... Ó íàñ â îòäåëåíèè íåäàâíî áûë äæåíòåëüìåí ñ àëüáóìèíîì 0,8 è îáùèì áåëêîì 2,7 íà ôîíå íåñïåöèôè÷åñêîãî ÿçâåííîãî êîëèòà.

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •